The progressive nature of type 2 diabetes mellitus leads to the need for insulin therapy in a significant proportion of patients. Very often start of insulin therapy in type 2 diabetes mellitus (T2DM) is associated with weight gain and a significant increase of hypoglycemia's risk. However, innovative options, such as fixed ratio combinations of glucagon-like peptide 1 receptor agonists (GLP-1RA) and basal insulin, minimize weight gain and hypoglycemia risks and allow a greater proportion of patients to achieve individual glycemic control goals without compromising safety parameters. This review includes a description of the randomized clinical trials, as well as the results of real clinical practice of the use of two currently existing fixed ration combinations of GLP-1RA and basal insulin - iDegLira and iGlarLixi.
Keyphrases
- glycemic control
- type diabetes
- weight gain
- end stage renal disease
- blood glucose
- weight loss
- body mass index
- rheumatoid arthritis
- ejection fraction
- newly diagnosed
- clinical practice
- insulin resistance
- stem cells
- peritoneal dialysis
- clinical trial
- ankylosing spondylitis
- disease activity
- metabolic syndrome
- risk assessment
- systemic lupus erythematosus
- bone marrow
- skeletal muscle
- adipose tissue
- human health
- patient reported
- case report